• All
  • Cardiovascular
  • Central Nervous System
  • Gastroenterology
  • Respiratory
  • Syncrosome News
Syncrosome Poster 6 OHDA Parkinson and dyskinesia

This poster has been presented at the last 2015 World Parkinson Congress in France, and shows interesting results concerning an antidyskinetic compound in a rat 6 OHDA Parkinson model. Dyskinesias are induced by LDopa, and various parameters are assessed, biochemical and symptomatic. Microdialysis is used to evaluate...

Immunization therapies, synuclein and Parkinson’s disease – multiple system atrophy

Vaccination is increasingly being investigated as a potential treatment for synucleinopathies, a group of neurodegenerative diseases including Parkinson's disease (synuclein Parkinson), multiple system atrophy, and dementia with Lewy bodies associated with α-synuclein pathology. All lack a causal therapy. Development of novel, disease-altering treatment strategies is...

Neurorescue and DHA on a 6OHDA preclinical Parkinson model

Preclinical data collected in models of preclinical Parkinson disease (PD) support the neuroprotective potential of omega-3 polyunsaturated fatty acids (n-3 PUFA)-enriched diet on the dopaminergic (DAergic) system. In this study, we investigated the effects of a n-3 PUFA rich diet using a neurorescue/neurorestorative paradigm....

Alpha-synuclein in Parkinson disease

Alpha Synuclein Parkinson: Formation and accumulation of misfolded protein aggregates are a central hallmark of several neurodegenerative diseases. In Parkinson’s disease (PD), the aggregation-prone protein alpha-synuclein (α-syn) is the culprit. In the past few years, another piece of the puzzle has been added with data suggesting...